LIVIVO - Search results -

Search results

Result 1 - 10 of total 62

Search options

Article ; Online: Isolated multiple neuropathy as clinical manifestation of leukemia relapse.

Esteller, D / Doncel-Moriano, A / Claro, M / Tardón, L / Navarro-Otano, J / Martínez-Hernández, E / Suárez-Lledó, M / Alejaldre, A

Revista de neurologia

2022 Volume 75, Issue 4, Page(s) 93–95

Abstract: Introduction: Neuroleukemia is a rare disorder of the peripheral nervous system due to leukemic cell infiltration.: Case report: We present the case of a 34-year-old patient with history of acute myelomonoblastic leukemia in remission that presented ... ...

Title translation	Neuropatía múltiple como manifestación clínica de una recidiva de leucemia.
Abstract	Introduction: Neuroleukemia is a rare disorder of the peripheral nervous system due to leukemic cell infiltration. Case report: We present the case of a 34-year-old patient with history of acute myelomonoblastic leukemia in remission that presented progressive paresis of the right median, bilateral facial, and left peroneal nerves. The electromyogram confirmed the diagnosis of multineuropathy. A PET-CT showed hypermetabolism of both sciatic, facial, and right median nerves. A bone marrow aspirate confirmed the leukemia relapse so a new round of chemotherapy was performed with improvement of the neurological deficit. Conclusion: Peripheral nervous system infiltration by leukemic cells can mimic multiple syndromes depending on the structures involved. The nerve-blood barrier acts as a defense of leukemic cells against chemotherapy and the immune system. Thus, the peripheral nervous system constitutes a reservoir of leukemic cells. Neuroleukemia should be considered in patients with history of acute leukemia who have isolated symptoms of the peripheral nerve.
MeSH term(s)	Adult ; Humans ; Leukemia ; Leukemic Infiltration ; Peripheral Nervous System Diseases/diagnosis ; Positron Emission Tomography Computed Tomography ; Recurrence
Language	Spanish
Publishing date	2022-07-19
Publishing country	Spain
Document type	Case Reports
ZDB-ID	1468278-3
ISSN	1576-6578 ; 0210-0010
ISSN (online)	1576-6578
ISSN	0210-0010
DOI	10.33588/rn.7504.2021367
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5003: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Usefulness of high-frequency ultrasonography in the evaluation and monitoring of sclerosing dermatoses: a cohort study.

Marti-Marti, I / Morgado-Carrasco, D / Podlipnik, S / Rizo-Potau, D / Bosch-Amate, X / Lledó, G M / Suárez-Lledó, M / Espinosa, G / Martínez, C / Mascaró, J M / Giavedoni, P

Clinical and experimental dermatology

2021 Volume 47, Issue 2, Page(s) 351–358

Abstract: Background: Monitoring of disease activity in sclerosing dermatoses (SD) can be challenging and tools to support clinical decision-making are lacking.: Aim: To analyse the impact of high-frequency ultrasonography (HFUS) on the clinical management of ... ...

Abstract	Background: Monitoring of disease activity in sclerosing dermatoses (SD) can be challenging and tools to support clinical decision-making are lacking. Aim: To analyse the impact of high-frequency ultrasonography (HFUS) on the clinical management of SD and to describe the US characteristics of disease activity. Methods: This was a cohort study of patients with various SD [morphoea, systemic sclerosis (SS) and chronic graft-versus-host disease (cGvHD)] who underwent HFUS between January 2017 and August 2019. HFUS criteria for diagnosing active SD were increased Doppler vascularity and/or meeting all B-mode greyscale US signs of activity. Discordance in SD activity between HFUS and clinical examination was evaluated at the time of the first US assessment. Changes in patient management were instituted after HFUS were recorded. Results: In total, 72 patients (31 with morphoea, 19 with SS and 22 with cGvHD), who underwent 163 HFUS sessions in total, were included. All HFUS-active morphoea lesions exhibited increased vascularity, and all HFUS-active SS exhibited dermal thickening and dermal hypoechogenicity. HFUS-active cGvHD displayed increased dermal thickness and loss of definition of the dermal-hypodermal junction, and there were signs of panniculitis in 80% of cases and of increased vascularity in 70%. Discordance in disease activity between clinical and HFUS evaluation was found in 17 (23.6%) patients. Changes in clinical management after HFUS were made for 14 (19.4%) patients: treatment discontinuation for 6 patients (42.9%), treatment initiation for 5 (35.7%), medication change for 2 (14.3%) and skin biopsy taken for 1 (7.1%). Conclusion: HFUS seems an efficacious support tool in the monitoring of SD activity with a notable impact on clinical management. Further studies are warranted to evaluate the impact of HFUS-supported management changes on SD outcomes.
MeSH term(s)	Adult ; Aged ; Cohort Studies ; Female ; Graft vs Host Disease/diagnostic imaging ; Humans ; Male ; Middle Aged ; Scleroderma, Localized/diagnostic imaging ; Scleroderma, Systemic/diagnostic imaging ; Skin/diagnostic imaging ; Skin/pathology ; Ultrasonography/methods
Language	English
Publishing date	2021-10-27
Publishing country	England
Document type	Journal Article
ZDB-ID	195504-4
ISSN	1365-2230 ; 0307-6938
ISSN (online)	1365-2230
ISSN	0307-6938
DOI	10.1111/ced.14903
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1278: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Increased Serum Levels of N-terminal pro-B-type Natriuretic Peptide (NT-proBNP) in Mobilized Healthy Donors with G-CSF: A Cohort Study.

Cid, Joan / Guinetti-Ortiz, Katia / Charry, Paola / Carbassé, Gloria / de Pablo-Miró, Mar / Rubia, Laura / Garcia, Marta / Alcaraz-Quiles, Jose / Cascos, Enric / Martínez-Cibrian, Nuria / Salas, María Queralt / Suárez-Lledó, Maria / Rosiñol, Laura / Fernández-Avilés, Francesc / Martínez, Carmen / Rovira, Montserrat / Lozano, Miquel

Transfusion medicine reviews

2024 Volume 38, Issue 2, Page(s) 150824

Abstract: Limited data regarding elevation of N-terminal pro-B-type natriuretic peptide (NT-proBNP) in mobilized donors with G-CSF is available. We extended these findings by examining serum NT-proBNP in a cohort study including 35 healthy donors and 69 patients ... ...

Abstract	Limited data regarding elevation of N-terminal pro-B-type natriuretic peptide (NT-proBNP) in mobilized donors with G-CSF is available. We extended these findings by examining serum NT-proBNP in a cohort study including 35 healthy donors and 69 patients who received G-CSF for CD34+ mobilization as well as 54 patients who did not receive G-CSF but who underwent collection of CD3+ cells for chimeric antigen receptor (CAR) T-cell manufacturing. No donor in the three cohorts experienced significant cardiac adverse events. NT-proBNP levels were measured before and after G-CSF administration and after finishing apheresis procedure. NT-proBNP increase was observed in mobilized healthy donors after G-CSF administration, but was not observed in mobilized or non-mobilized patients. Only in the cohort of healthy donors, pairwise comparisons using Wilcoxon signed ranks test showed a significant increase between the mean serum NT-proBNP level after G-CSF administration and the mean serum NT-proBNP level measured before G-CSF administration (231.09 ± 156.15 pg/mL vs. 58.88 ± 26.84 pg/mL; P < .01). No correlation was observed between NT-proBNP increase and G-CSF dose (r
MeSH term(s)	Humans ; Natriuretic Peptide, Brain/blood ; Peptide Fragments/blood ; Male ; Granulocyte Colony-Stimulating Factor/blood ; Female ; Hematopoietic Stem Cell Mobilization/methods ; Middle Aged ; Adult ; Cohort Studies ; Aged ; Blood Donors ; Antigens, CD34
Chemical Substances	Natriuretic Peptide, Brain (114471-18-0) ; pro-brain natriuretic peptide (1-76) ; Peptide Fragments ; Granulocyte Colony-Stimulating Factor (143011-72-7) ; Antigens, CD34
Language	English
Publishing date	2024-03-15
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	639107-2
ISSN	1532-9496 ; 0887-7963
ISSN (online)	1532-9496
ISSN	0887-7963
DOI	10.1016/j.tmrv.2024.150824
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 2239: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Improving the EASIX' predictive power for NRM in adults undergoing allogeneic hematopoietic cell transplantation.

Escribano-Serrat, Silvia / Rodríguez-Lobato, Luis Gerardo / Suárez-Lledó, María / Pedraza, Alexandra / Charry, Paola / Cid, Joan / Lozano, Miquel / Esteve, Jordi / Rosiñol, Laura / Fernández-Avilés, Francesc / Carreras, Enric / Díaz-Ricart, Maribel / Martínez, Carmen / Rovira, Montserrat / Salas, María Queralt

Bone marrow transplantation

2024

Language	English
Publishing date	2024-03-23
Publishing country	England
Document type	Letter
ZDB-ID	632854-4
ISSN	1476-5365 ; 0268-3369 ; 0951-3078
ISSN (online)	1476-5365
ISSN	0268-3369 ; 0951-3078
DOI	10.1038/s41409-024-02267-6
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 2168: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: EASIX and cardiac adverse events after allogeneic hematopoietic cell transplantation.

Tolosa-Ridao, Carles / Cascos, Enric / Rodríguez-Lobato, Luis Gerardo / Pedraza, Alexandra / Suárez-Lledó, María / Charry, Paola / Solano, María Teresa / Martinez-Sanchez, Julia / Cid, Joan / Lozano, Miquel / Rosiñol, Laura / Esteve, Jordi / Urbano-Ispizua, Álvaro / Fernández-Avilés, Francesc / Martínez, Carmen / Carreras, Enric / Díaz-Ricart, Maribel / Rovira, Montserrat / Salas, María Queralt

Bone marrow transplantation

2024

Abstract: This study investigates the interaction between endothelial activation, indirectly measured using EASIX, and the probability of presenting cardiac adverse events (CAE) during the first year after allo-HCT. The 437 consecutive adults undergoing PB allo- ... ...

Abstract	This study investigates the interaction between endothelial activation, indirectly measured using EASIX, and the probability of presenting cardiac adverse events (CAE) during the first year after allo-HCT. The 437 consecutive adults undergoing PB allo-HCT from 2012 and 2021 were included. EASIX was retrospectively calculated before and during the first 6 months after allo-HCT and transformed to log2-base to conduct the statistical analysis. The median age was 53, 46 (10.5%) patients had previous history of cardiac disease, MAC allo-HCTs were performed in 186 (42.6%) patients, and PTCY was administered in 242 (55.5%). The 1-year incidence of CAE was 12.6% (n = 55). The most prevalent cardiac events were heart failure and arrhythmias, 32.7% and 23.6% respectively, and the day +100 mortality rate of these patients was 40.5%. During the first 6 months after allo-HCT, EASIX trends were significantly higher in patients who developed CAE. Regression analyses confirmed that higher log2-EASIX values were predictors for higher risk for CAE during the first year after allo-HCT. This analysis identifies a significant association between higher endothelial activation, indirectly measured using EASIX, and higher risk for cardiac toxicity diagnosed during the first year after allo-HCT and extends the applicability of EASIX for identifying patients at risk for CAE.
Language	English
Publishing date	2024-03-23
Publishing country	England
Document type	Journal Article
ZDB-ID	632854-4
ISSN	1476-5365 ; 0268-3369 ; 0951-3078
ISSN (online)	1476-5365
ISSN	0268-3369 ; 0951-3078
DOI	10.1038/s41409-024-02270-x
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 2168: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Cyclophosphamide-free mobilisation increases safety while preserving the efficacy of autologous haematopoietic stem cell transplantation in refractory Crohn's disease patients.

Giordano, Antonio / Rovira, Montserrat / Veny, Marisol / Barastegui, Rebeca / Marín, Pedro / Martínez, Carmen / Fernández-Avilés, Francesc / Suárez-Lledó, María / Domènech, Ariadna / Serrahima, Anna / Lozano, Miquel / Cid, Joan / Ordás, Ingrid / Fernández-Clotet, Agnés / Caballol, Berta / Gallego, Marta / Vara, Alejandro / Masamunt, Maria Carme / Giner, Àngel /

Teubel, Iris / Esteller, Miriam / Corraliza, Anna María / Panés, Julian / Salas, Azucena / Ricart, Elena

Journal of Crohn's & colitis

2024

Abstract: Background and aim: Autologous haematopoietic stem cell transplantation [AHSCT] is a therapeutic option for refractory Crohn's disease [CD]. However, high adverse event rates related to chemotherapy toxicity and immunosuppression limit its applicability. ...

Abstract	Background and aim: Autologous haematopoietic stem cell transplantation [AHSCT] is a therapeutic option for refractory Crohn's disease [CD]. However, high adverse event rates related to chemotherapy toxicity and immunosuppression limit its applicability. This study aims to evaluate AHSCT's safety and efficacy using a cyclophosphamide (Cy)-free mobilisation regimen. Methods: A prospective observational study included 14 refractory CD patients undergoing AHSCT between June 2017 and October 2022. The protocol involved outpatient mobilisation with G-CSF 12-16 μg/kg/daily for 5 days, and optional Plerixafor 240 μg/d (1-2 doses) if the CD34+ cell count target was unmet. Standard conditioning with Cy and anti-thymocyte globulin was administered. Clinical, endoscopic, and radiological assessments were conducted at baseline and during follow-up. Results: All patients achieved successful outpatient mobilisation (7 patients needed Plerixafor) and underwent transplantation. Median follow-up was 106 weeks (IQR 52-348). No mobilisation-related serious adverse events (SAEs) or CD worsening occurred. Clinical and endoscopic remission rates were 71% and 41.7% at 26 weeks, 64% and 25% at 52 weeks, and 71% and 16.7% at the last follow-up. The percentage of patients who restarted CD therapy for clinical relapse and/or endoscopic/radiological activity was 14% at 26 weeks, 57% at 52 weeks, and 86% at the last follow-up. Peripheral blood cell populations and antibody levels post-AHSCT were comparable to Cy-based mobilisation. Conclusions: Cy-free mobilisation is safe and feasible in refractory CD patients undergoing AHSCT. Although relapse occurs in a significant proportion of patients, clinical and endoscopic responses are achieved upon CD-specific therapy reintroduction.
Language	English
Publishing date	2024-05-17
Publishing country	England
Document type	Journal Article
ZDB-ID	2390120-2
ISSN	1876-4479 ; 1873-9946
ISSN (online)	1876-4479
ISSN	1873-9946
DOI	10.1093/ecco-jcc/jjae076
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6634: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Applicability and validation of different prognostic scores in allogeneic hematopoietic cell transplant (HCT) in the post-transplant cyclophosphamide era.

Salas, María Queralt / Rodríguez-Lobato, Luis Gerardo / Charry, Paola / Suárez-Lledó, Maria / Pedraza, Alexandra / Solano, María Teresa / Arcarons, Jordi / Cid, Joan / Lozano, Miquel / Rosiñol, Laura / Esteve, Jordi / Carreras, Enric / Fernández-Avilés, Francesc / Martínez, Carmen / Rovira, Montserrat

Hematology, transfusion and cell therapy

2023

Abstract: We investigated the predictive capacity of six prognostic indices [Karnofsky Performance Status (KPS), Hematopoietic Cell Transplant-Specific Comorbidity Index (HCT-CI), Disease Risk Index (DRI), European Bone Marrow Transplantation (EBMT) and Revised ... ...

Abstract	We investigated the predictive capacity of six prognostic indices [Karnofsky Performance Status (KPS), Hematopoietic Cell Transplant-Specific Comorbidity Index (HCT-CI), Disease Risk Index (DRI), European Bone Marrow Transplantation (EBMT) and Revised Pre-Transplantation Assessment of Mortality (rPAM) Scores and Endothelial Activation and Stress Index (EASIX)] in 205 adults undergoing post-transplant cyclophosphamide (PTCy)-based allo-HCT. KPS, HCT-CI, DRI and EASIX grouped patients into higher and lower risk strata. KPS and EASIX maintained appropriate discrimination for OS prediction across the first 2 years after allo-HCT [receiver operating characteristic curve (area under the curve (AUC) > 55 %)]. The discriminative capacity of DRI and HCT-CI increased during the post-transplant period, with a peak of prediction at 2 years (AUC of 61.1 % and 61.8 %). The maximum rPAM discriminative capacity was at 1 year (1-year AUC of 58.2 %). The predictive capacity of the EBMT score was not demonstrated. This study validates the discrimination capacity for OS prediction of KPS, HCT-CI, DRI and EASIX in PTCy-based allo-HCT.
Language	English
Publishing date	2023-10-12
Publishing country	Brazil
Document type	Journal Article
ISSN	2531-1387
ISSN (online)	2531-1387
DOI	10.1016/j.htct.2023.07.008
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Current outcomes of SARS-CoV-2 Omicron variant infection in high-risk haematological patients treated early with antivirals.

Aiello, Tommaso-Francesco / Puerta-Alcalde, Pedro / Chumbita, Mariana / Lopera, Carlos / Monzó, Patricia / Cortes, Albert / Fernández-Avilés, Francesc / Suárez-Lledó, María / Correa, Juan / Ortiz-Maldonado, Valentín / Cuesta, Genoveva / Martinez-Cibrian, Nuria / Esteve, Jordi / Marcos, Maria Ángeles / Mensa, Josep / Soriano, Alex / Garcia-Vidal, Carolina

The Journal of antimicrobial chemotherapy

2023 Volume 78, Issue 6, Page(s) 1454–1459

Abstract: Objectives: We aimed to describe the clinical outcomes and duration of viral shedding in high-risk patients with haematological malignancies hospitalized with COVID-19 during Omicron variant predominance who received early treatment with antivirals.: ... ...

Abstract	Objectives: We aimed to describe the clinical outcomes and duration of viral shedding in high-risk patients with haematological malignancies hospitalized with COVID-19 during Omicron variant predominance who received early treatment with antivirals. Methods: We conducted a prospective observational study on high-risk haematological patients admitted in our hospital between December 2021 and March 2022. We performed detection techniques on viral subgenomic mRNAs until negative results were obtained to document active, prolonged viral replication. Results: This analysis included 60 consecutive adults with high-risk haematological malignancies and COVID-19. All of these patients underwent early treatment with remdesivir. Thirty-two (53%) patients received combined antiviral strategies, with sotrovimab or hyperimmune plasma being added to remdesivir. The median length of viral replication-as measured by real-time RT-PCR and/or subgenomic RNA detection-was 20 (IQR 14-28) days. Prolonged viral replication (6 weeks after diagnosis) was documented in six (10%) patients. Only two patients had prolonged infection for more than 2 months. Overall mortality was 5%, whereas COVID-19-related mortality was 0%. Conclusions: Current outcomes of high-risk patients with haematological malignancies hospitalized with COVID-19 during Omicron variant predminance are good with the use of early antiviral strategies. Persistent viral shedding is uncommon.
MeSH term(s)	Adult ; Humans ; Antiviral Agents/therapeutic use ; COVID-19 ; Dermatologic Agents ; Hematologic Neoplasms/complications ; Hematologic Neoplasms/drug therapy ; SARS-CoV-2 ; Subgenomic RNA
Chemical Substances	Antiviral Agents ; Dermatologic Agents ; Subgenomic RNA
Language	English
Publishing date	2023-04-11
Publishing country	England
Document type	Journal Article ; Observational Study ; Research Support, Non-U.S. Gov't
ZDB-ID	191709-2
ISSN	1460-2091 ; 0305-7453
ISSN (online)	1460-2091
ISSN	0305-7453
DOI	10.1093/jac/dkad105
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1197: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 124: Show issues

Order via subito

Details ▾

Article ; Online: Impact of letermovir prophylaxis in CMV reactivation and disease after allogenic hematopoietic cell transplantation: a real-world, observational study.

Brusosa, Marc / Ruiz, Sonia / Monge, Inés / Solano, María Teresa / Rosiñol, Laura / Esteve, Jordi / Carreras, Enric / Marcos, M Ángeles / Riu, Gisela / Carcelero, Esther / Martinez, Carmen / Fernández-Avilés, Francesc / Rovira, Montserrat / Suárez-Lledó, María / Salas, María Queralt

Annals of hematology

2023 Volume 103, Issue 2, Page(s) 609–621

Abstract: Letermovir for CMV prevention in CMV-seropositive adults undergoing allo-HCT was implemented at our program in 2021. This study investigates the results from the use of letermovir. The study includes all the 140 CMV-seropositive patients who underwent an ...

Abstract	Letermovir for CMV prevention in CMV-seropositive adults undergoing allo-HCT was implemented at our program in 2021. This study investigates the results from the use of letermovir. The study includes all the 140 CMV-seropositive patients who underwent an allo-HCT during the years 2020, 2021, and 2022 at our institution. Thirty-eight (27.4%) of these patients received letermovir, administered from day + 7 to day + 100 and restarted if patients were on treatment with steroids. The day + 180 and 1-year cumulative incidences of CMV reactivation were 5.3% and 12.1% for patients who received letermovir and 52.9% and 53.9% for those who did not (P < 0.001) (HR 0.19, P < 0.001). Four (10.5%) of these thirty-eight patients had a CMV reactivation, but only 2 (5.3%) cases occurred during the administration of letermovir. During the first year after allo-HCT, 13 (9.2%) patients had CMV disease; the day + 180 and 1-year cumulative incidences were 2.6% and 6.0% for patients who received letermovir and 9.9% and 12.3% for those who did not (P = 0.254) (HR 1.01, P = 0.458). Two (4.2%) of the patients included in the letermovir group had CMV disease, but both of them after letermovir discontinuation. Letermovir induced a protective effect on CMV reactivation risk, but its use was not associated with a significant reduction of CMV disease. The fact that the CMV disease in patients who received letermovir occurred after the discontinuation of the drug, questions whether CMV prophylaxis should be used in patients with high risk for CMV reactivation or disease.
MeSH term(s)	Adult ; Humans ; Cytomegalovirus Infections/epidemiology ; Cytomegalovirus Infections/etiology ; Cytomegalovirus Infections/prevention & control ; Cytomegalovirus ; Antiviral Agents/therapeutic use ; Hematopoietic Stem Cell Transplantation/adverse effects ; Acetates ; Quinazolines
Chemical Substances	letermovir (1H09Y5WO1F) ; Antiviral Agents ; Acetates ; Quinazolines
Language	English
Publishing date	2023-11-14
Publishing country	Germany
Document type	Observational Study ; Journal Article
ZDB-ID	1064950-5
ISSN	1432-0584 ; 0939-5555 ; 0945-8077
ISSN (online)	1432-0584
ISSN	0939-5555 ; 0945-8077
DOI	10.1007/s00277-023-05542-6
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Uh III Zs.181: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Assessment of UL56 Mutations before Letermovir Therapy in Refractory Cytomegalovirus Transplant Recipients.

Santos Bravo, Marta / Tilloy, Valentin / Plault, Nicolas / Palomino, Sonsoles Sánchez / Mosquera, María Mar / Navarro Gabriel, Mireia / Fernández Avilés, Francesc / Suárez Lledó, María / Rovira, Montserrat / Moreno, Asunción / Linares, Laura / Bodro, Marta / Hantz, Sébastien / Alain, Sophie / Marcos, María Ángeles

Microbiology spectrum

2022 Volume 10, Issue 2, Page(s) e0019122

Abstract: ... De ... ...

Abstract	De novo
MeSH term(s)	Acetates ; Antiviral Agents/pharmacology ; Antiviral Agents/therapeutic use ; Cytomegalovirus/genetics ; Cytomegalovirus Infections/drug therapy ; Drug Resistance, Viral/genetics ; Humans ; Mutation ; Quinazolines ; Recurrence ; Transplant Recipients
Chemical Substances	Acetates ; Antiviral Agents ; Quinazolines ; letermovir (1H09Y5WO1F)
Language	English
Publishing date	2022-03-28
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2807133-5
ISSN	2165-0497 ; 2165-0497
ISSN (online)	2165-0497
ISSN	2165-0497
DOI	10.1128/spectrum.00191-22
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

To top

Your last searches

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito